Skip to main content

Tattoos May Increase Risk of Malignant Lymphoma

Medically reviewed by Carmen Pope, BPharm. Last updated on May 29, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, May 29, 2024 -- Tattoo exposure is associated with an increased risk of several malignant lymphoma subtypes, according to a study published online in the June issue of eClinicalMedicine.

Christel Nielsen, Ph.D., from Lund University in Sweden, and colleagues used Swedish National Authority Registers to investigate the association between tattoo exposure and overall malignant lymphoma as well as lymphoma subtypes. Analysis included 1,398 incident cases of malignant lymphoma diagnosed between 2007 and 2017 in individuals aged 20 to 60 years and matched (1:3) controls (4,193 cases).

The researchers found that tattooed individuals had a higher adjusted risk of overall lymphoma (incidence rate ratio [IRR], 1.21; 95 percent confidence interval [CI], 0.99 to 1.48). Highest risk of lymphoma was seen in individuals with less than two years between their first tattoo and the index year (IRR, 1.81; 95 percent CI, 1.03 to 3.20). With intermediate exposure duration (three to 10 years), the risk decreased but increased again in individuals who received their first tattoo ≥11 years before the index year (IRR, 1.19; 95 percent CI, 0.94 to 1.50). There was no evidence of increasing risk with a larger area of total tattooed body surface. Tattoo exposure-associated risk was highest for diffuse large B-cell lymphoma (IRR, 1.30; 95 percent CI, 0.99 to 1.71) and follicular lymphoma (IRR, 1.29; 95 percent CI, 0.92 to 1.82).

"For the individual, it is good to know that tattoos can affect your health, and that you should turn to your health care provider if you experience symptoms that you believe could be related to your tattoo," Nielsen said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma

WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell...

Abrocitinib Effective, Tolerated for Prurigo Nodularis, Chronic Pruritus

TUESDAY, June 25, 2024 -- For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1 inhibitor, is effective and well...

ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma

THURSDAY, June 20, 2024 -- For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.